
Daniel Del Castillo Désjardins, Arantxa Cabrera Vilanova, Margarida Vives Espelta, María Rosa Prieto Butillé, Fátima Sabench Pereferrer*

Hospital Universitario de Sant Joan de Reus, Universitat Rovira i Virgili, Reus, Tarragona, Spain

*Corresponding author.
E-mail address: fatima.sabench@urv.cat
(F. Sabench Pereferrer).

2173-5077/
© 2016 AEC. Published by Elsevier España, S.L.U. All rights reserved.

Primary Adrenal Lymphoma; a Rare Entity in the Differential Diagnosis of Suprarenal Tumours☆

Linfoma adrenal primario; una entidad poco frecuente en el diagnóstico diferencial de las tumoraciones suprarrenales

The general use of techniques like computed tomography (CT) and magnetic resonance imaging for the follow-up of oncological patients has increased the detection of adrenal masses.1 These lesions are a clinical challenge due to the diagnostic doubts generated about their nature, especially in patients with a history of neoplasms in the lungs, breasts or colon.1,2

We present the case of a 64-year-old male patient, with no prior medical history of interest, who had been treated surgically one year earlier for adenocarcinoma of the sigma (stage pT3N0M0) and had afterwards received adjuvant chemotherapy with the XELOX regimen. The follow-up CT 9 months after surgery detected the appearance of a new left adrenal lesion. The mass was oval and had moderate attenuation (Fig. 1). Positon emission tomography (PET) presented increased metabolic activity with a maximum SUV of 16.47 (Fig. 2). Given the patient’s recent medical history, the initially suspected diagnosis was adrenal metastasis of the colon adenocarcinoma. Because it was a rapidly-growing lesion and appeared to be resectable on the imaging studies, we decided to conduct laparoscopic left adrenalectomy to make a definitive diagnosis. En bloc resection of the lesion was carried out. The histopathologic study reported the presence of infiltration of the suprarenal gland by a diffuse large B-cell lymphoma with a high cell proliferation rate. The patient received treatment with 6 cycles of a chemotherapy regimen including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), as well as intrathecal prophylaxis. The patient continues to be disease-free one year later.

Adrenal involvement in the context of disseminated non-Hodgkin’s lymphoma is uncommon.2,3 Nonetheless, primary adrenal lymphoma (PAL) is also an unusual condition.1–3 Extranal lymphomas located in the gland tissue represent only 3%, and the thyroid is the most frequent location.4,5

☆ Please cite this article as: Sagarra Cebolla E, López Baena JÁ, Carrasco Muñoz S, del Corral Rodriguez J, Lozano Lominchar P. Linfoma adrenal primario; una entidad poco frecuente en el diagnóstico diferencial de las tumoraciones suprarrenales. Cir Esp. 2016;94:607–609.
Only 1% of these tumours are diagnosed incidentally on imaging tests. The echogenicity of these lesions is variable and no specific pattern has been reported to provide an ultrasound diagnosis. On CT, which is currently considered the test of choice in the diagnosis of adrenal masses, the lesions are characterised by a general increase in the size of the gland, maintaining its architecture but presenting variable densities. It is frequent to find them as low uptake lesions with moderate uptake after the administration of intravenous contrast. Areas of necrosis and intraparenchymal haemorrhages may also be observed. On MRI, they present as isointense as well as hypointense lesions in T1 and hyperintense in T2. PET studies always detect increased metabolic activity.

The diagnosis should be confirmed by histology. Given the suspicion, gland excision or ultrasound/CT-guided core-needle biopsy are the diagnostic tests of choice. The differential diagnosis should be established with adrenal tuberculosis, haematomas, infections, non-functioning adenomas, phaeochromocytoma, adrenal carcinoma and metastasis of adenocarcinoma of the lungs, breasts, kidneys, pancreas or melanoma. If the lesion is resectable, the treatment of choice should be surgical excision, which should be complemented with chemotherapy and adjuvant radiotherapy, although the actual benefit of radiotherapy has not been well established. The most frequently used chemotherapy regimen is CHOP with rituximab since the most recent studies have demonstrated that the combination of rituximab increases survival.

The prognosis is generally unfavourable. The best survival rates are observed when the involvement is unilateral and when there is a complete response to chemotherapy. Surgical resection is a factor for a positive prognosis in most univariate analyses, although it loses its significance in the multivariate analyses. Factors for a poor prognosis include advanced age, tumour size, elevated LDH or adrenal insufficiency at the time of diagnosis and bilateral adrenal involvement.

In conclusion, adrenal lymphoma is an uncommon condition whose diagnosis is generally reached after the excision of the affected gland. The prognosis is unfavourable, although treatment with immunotherapy improves patient prognosis.

**Funding**

No funding was required to complete this manuscript.

**REFERENCES**


Elena Sagarraga Cebolla**, Jose Ángel López Baena**, Sergio Carrasco Muñoz*, Javier del Corral Rodríguez*, Pablo Lozano Lominchar*

**Servicio de Cirugía General, Hospital General Universitario Gregorio Marañón, Madrid, Spain

*Servicio de Radiodiagnóstico, Hospital General Universitario Gregorio Marañón, Madrid, Spain

*Corresponding author.
E-mail address: esc_zgz@hotmail.com (E. Sagarraga Cebolla).

2173-5077/
© 2016 AEC. Published by Elsevier España, S.L.U. All rights reserved.

# Modified Karydakis Procedure for Giant Pilonidal Sinus

Técnica de Karydakis modificada para el tratamiento del sinus pilonidal gigante

The Karydakis technique for the treatment of pilonidal sinus is a widely accepted procedure by the scientific community.1,2 It involves asymmetric resection to flatten the natal cleft and lateralize the surgical suture,3 creating a flap from the medial edge to cover the defect and close the wound, avoiding the intergluteal cleft.

We present the cases of 3 patients with pilonidal sinus larger than 12 cm, with lateral/bilateral projections of the pseudocyst (Table 1). In all cases, reconstruction was performed with the Karydakis technique (Figs. 1 and 2). In doing so, a paramedian line was drawn 2 cm from the median line (becoming the new medial axis) displaced towards the side of the secondary orifice where an induration was palpated, caused by the pilonidal sinus; the caudal end of the incision was displaced 1 cm more to the side in order to distance the wound from the anus. The medial edge of the incision followed a curved path that crossed the midline, including the primary orifice(s), and the lateral edge was symmetrical with the medial edge to avoid the scar resting on the midline.3,4 All the affected tissue was resected until the sacrococcygeal fascia was reached. In the subcutaneous fatty tissue of the medial edge of the wound, 1 cm underneath the skin, a flap was created from the fatty tissue some 2 cm along the length of the wound. The lower lip of the flap was sutured to the rectosacral fascia on the midline with interrupted sutures, which caused lateral displacement of the flap. Another layer of interrupted sutures was used to deal with the raw surface, reducing dead space. However, our patients presented bilateral projections that required extending the excision. Therefore, in keeping with the principles of the Karydakis technique at all times, the fatty

<table>
<thead>
<tr>
<th>Table 1 – Clinical and Surgical Data of the Patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal data</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Patient 1</td>
</tr>
<tr>
<td>Patient 2</td>
</tr>
<tr>
<td>Patient 3</td>
</tr>
</tbody>
</table>

ML, midline; PO, primary orifice; SO, secondary orifice; IC, intergluteal cleft.

Please cite this article as: Martínez Sanz N, Peña Ros E, Sánchez Cifuentes A, Benavides Buleje JA, Albarracín Marín-Blazquez A. Técnica de Karydakis modificada para el tratamiento del sinus pilonidal gigante. Cir Esp. 2016;94:609–611.